midostaurin
Sign in to saveAlso known as PKC412, CGP 41231, CGP 41251, N-benzoylstaurosporine, benzoylstaurosporine, PKC 412, 4'-N-benzoylstaurosporine, CGP-41251
Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
Key facts
- Drug.IUPAC_name
- (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one
- Drug.image
- Midostaurin skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 180
- Drug.image2
- Midostaurin molecule ball.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 220
- Drug.alt2
- Ball-and-stick model of the midostaurin molecule
- Drug.tradename
- Rydapt
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EX10
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.IUPHAR_ligand
- 5702
- Drug.CAS_number
- 120685-11-2
via Wikipedia infobox
Research
1,030 papers- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.The New England journal of medicine · 2017
- Midostaurin.2012
- Midostaurin: First Global Approval.Drugs · 2017
- Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis.American journal of therapeutics · 2023
- Midostaurin approved for FLT3-mutated AML.Blood · 2017
via PubMed
~2 min read
Encyclopedic overview
4 sectionsContents
- AML and MDS
- Systemic mastocytosis
- Side effects
- References
Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “midostaurin” article, available under the CC BY-SA 4.0 licence.